JL5 only has weak inhibition of BMPR2 (IC50 8 μM) compared to its inhibition of the BMP type 1 receptors (5 nM), which may explain its lack of suppression of BMPR2 signaling in some cancer cells. This evidence concerns the gene BMPR2 and cancer.